
Illumina ILMN
$ 135.16
0.22%
Quarterly report 2025-Q3
added 10-31-2025
Illumina Interest Expense 2011-2025 | ILMN
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Illumina
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -292 M | -29 M | 61 M | 49 M | - | 52 M | 57 M | 37 M | 43 M | - | 41.7 M | 39.7 M | 37.8 M | 24.6 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 61 M | -292 M | 10.1 M |
Quarterly Interest Expense Illumina
| 2025-Q3 | 2025-Q2 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9 M | 107 M | 4 M | -332 M | 18 M | 1 M | 20 M | - | - | 6 M | 6 M | - | 14 M | 16 M | 19 M | - | 11 M | 11 M | 11 M | - | 11 M | 15 M | 15 M | - | 15 M | 11 M | 11 M | - | 10 M | 8 M | 8 M | - | 9 M | 8 M | 8 M | - | 12.8 M | 11.2 M | 11.2 M | - | 11 M | 9.92 M | 9.74 M | - | 9.95 M | 10 M | 9.75 M | - | 9.48 M | 9.51 M | 9.2 M | - | 8.8 M | 9.42 M | 7.39 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 107 M | -332 M | 4.75 M |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M | ||
|
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M | ||
|
Burning Rock Biotech Limited
BNR
|
1.54 M | $ 16.38 | 3.97 % | $ 170 M | ||
|
Accelerate Diagnostics
AXDX
|
235 K | - | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | ||
|
BioNano Genomics
BNGO
|
-10.1 M | $ 1.6 | -1.23 % | $ 2.03 M | ||
|
Castle Biosciences
CSTL
|
1 K | $ 39.39 | 1.97 % | $ 1.09 B | ||
|
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | ||
|
Danaher Corporation
DHR
|
-56 M | $ 228.73 | 0.98 % | $ 167 B | ||
|
DarioHealth Corp.
DRIO
|
-31 K | $ 11.97 | 0.67 % | $ 340 M | ||
|
DexCom
DXCM
|
20.3 M | $ 67.19 | 0.34 % | $ 25.9 B | ||
|
Exact Sciences Corporation
EXAS
|
18.6 M | $ 101.46 | -0.04 % | $ 18.8 B | ||
|
Fulgent Genetics
FLGT
|
561 K | $ 27.23 | 0.31 % | $ 823 M | ||
|
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M | ||
|
Genetic Technologies Limited
GENE
|
15.2 K | - | - | $ 7.1 B | ||
|
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | ||
|
CareDx, Inc
CDNA
|
1.34 M | $ 20.72 | 0.78 % | $ 1.11 B | ||
|
Celcuity
CELC
|
2.11 M | $ 105.02 | -0.22 % | $ 4.14 B | ||
|
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K | ||
|
Anixa Biosciences
ANIX
|
500 K | $ 3.41 | -4.75 % | $ 109 K | ||
|
Co-Diagnostics
CODX
|
106 K | $ 0.33 | -3.34 % | $ 9.68 M | ||
|
Guardant Health
GH
|
-42.6 M | $ 103.82 | 1.72 % | $ 12.7 B | ||
|
IQVIA Holdings
IQV
|
670 M | $ 223.38 | 0.52 % | $ 40.5 B | ||
|
Aspira Women's Health
AWH
|
106 K | - | -6.19 % | $ 10.5 M | ||
|
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | ||
|
Charles River Laboratories International
CRL
|
-16.5 M | $ 197.73 | 2.46 % | $ 10.2 B | ||
|
Quotient Limited
QTNT
|
2.72 M | - | -11.32 % | $ 1.1 M | ||
|
Quest Diagnostics Incorporated
DGX
|
30 M | $ 184.0 | 0.82 % | $ 20.4 B | ||
|
Biodesix
BDSX
|
8.26 M | $ 7.85 | - | $ 1.02 B | ||
|
Laboratory Corporation of America Holdings
LH
|
208 M | $ 264.75 | 0.22 % | $ 22.2 B | ||
|
ICON Public Limited Company
ICLR
|
337 M | $ 187.27 | 0.37 % | $ 15.4 B | ||
|
IDEXX Laboratories
IDXX
|
29.8 M | $ 707.12 | 0.41 % | $ 58.3 B | ||
|
Lantheus Holdings
LNTH
|
37.2 M | $ 66.85 | 0.35 % | $ 4.63 B | ||
|
Agilent Technologies
A
|
81 M | $ 140.96 | 0.93 % | $ 42.9 B | ||
|
Mettler-Toledo International
MTD
|
74.6 M | $ 1 405.6 | 0.84 % | $ 29.8 B | ||
|
Myriad Genetics
MYGN
|
1.1 M | $ 7.22 | 0.14 % | $ 654 M | ||
|
Biomerica
BMRA
|
367 | $ 2.53 | -1.94 % | $ 5.81 M | ||
|
Bioventus
BVS
|
1.29 M | $ 7.64 | 1.13 % | $ 479 M | ||
|
NeoGenomics
NEO
|
-379 K | $ 11.87 | 0.16 % | $ 1.5 B | ||
|
Neogen Corporation
NEOG
|
38.1 M | $ 6.82 | -0.66 % | $ 1.48 B | ||
|
Check-Cap Ltd.
CHEK
|
13 K | - | - | $ 9.42 M | ||
|
Motus GI Holdings
MOTS
|
211 | - | -34.28 % | $ 263 K |